Study of the safety of SGLT-2 inhibitors for heart failure patients with type 2 diabetes mellitus

Study of the safety of SGLT-2 inhibitors for heart failure patients with type 2 diabetes mellitus - SGLT-2 inhibitors for volume overload of heart failure patients with diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018996

Enrollment

Registered

2015-09-14

Start date

2015-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure patients with type 2 diabetes mellitus

Interventions

Administration of ipragliflozin 12.5 mg once a day. When it is insufficiently effective, it can be increased to 50 mg once a day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Type 2 diabetes with HbA1c >=7.0% and <12.0% 2) Physical findings of vloume overload 3) Loop diuretic administration of furosemide 20mg, azosemide 30mg or torasemide 4mg in a day 4) Written informed consent is obtained

Exclusion criteria

Exclusion criteria: 1) Type 1 diabetes 2) With severe renal dysfunction (eGRF <30 mL/min or patient undergoing artificial dialysis) 3) Heart failure patient whose NYHA functional classification is IV 4) SGLT-2 inhibitor has been administered from admission to registration 5) Physicians and other staff have been deemed inappropriate for registration of this study

Design outcomes

Primary

Measure	Time frame
The usage dose of loop, thiazides diuretics and tolvaptan at 4 weeks and 24 weeks.	—

Countries

Japan

Contacts

Public ContactYoshiaki Kubota

Nippon Medical School Department of Cardiovascular Medicine

ykubota@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026